fashion -WSS

fashion

author：fashion 2025-09-06 04:34:01 - browse：27

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Novo pauses ads for weight loss drug Wegovy amid demand

WSS

Grail spinoff by Illumina should end disastrous merger attempt

HCA sued by state AG for quality issues at Mission Health

Medicare drug price negotiation hasn't dried up venture capital

Violet CEO on training clinicians to promote more inclusive care

Mom launches Girl Scout troop for LGBTQ youth in Texas

Editas, Vertex strike deal on CRISPR

hotspot

fashion

entertainment

In age of alternative facts, a scholarly course on calling out crap

Senate panel passes drug pricing bills, but drops one PBM reform

United colonoscopy coverage change 'may cost lives,' doctors say

Living organ donors deserve priority status for transplants

Heart attack and stroke risk calculators need revising

SNAP should offer more nutrition education

After affirmative action ruling, medical educators look to 'holistic review'

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

entertainment

Grail spinoff by Illumina should end disastrous merger attempt

Carvykti CAR

Three trends to watch in biotech in 2024

Novo pauses ads for weight loss drug Wegovy amid demand

Timeline: Key moments in fight for gay rights

Can medical device makers keep up in the race to treat obesity?

hotspot

focus

Wikipedia

focus